课题基金 / 基金详情

SMARTdrugs_Supramolecular agents as radiotheranostic drugs

SMARTdrugs_Supramolecular agents as radiotheranostic drugs
SMARTdrugs_超分子药物作为放射治疗药物
批准号:
10091247
负责人:
金额:
$93.34万
依托单位:
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine. The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound. By using the self-assembly of host-guest supramolecular coordination complexes and molecularly interlocked molecules as scaffolds for creating supramolecular radiotheranostic drugs, new methodsfor radiotheranostic synthesisthat break away from conventional medicinal chemistry concept will be introduced. SMARTdrugs will establish a proof-of-concept demonstrating the utility of non-covalent systems in the design of multifunctional radiotheranostic agents with tailored pharmacokinetics, and their application in challenging drug-delivery scenarios including targeted delivery to cancers of the lung and brain. Our 3 main objectives: Objective 1 – Develop new chemical landscapes using non-covalent bonding to create functionalised supramolecular compounds for cancer-specific theranostics Objective 2 – Elucidate the key relationships between supramolecular radiotheranostics and the complex tumour microenvironment that determine drug efficacy in vivo Objective 3 – Perform head-to-head studies to establish a proof-of-principle that supramolecular chemistry is a viable alternative to classical radiopharmaceutical design The long-term goal is to establish a new chemical landscape for radiotheranostic design, and to facilitate clinical translation of this new technology. Successful experiments will lay the foundations for exploiting supramolecular chemistry in the wider context of drug delivery and theranostics, and for studying biological interactions at the cellular to whole-organism levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于LLM的Agents决策偏差研究——从处置效应案例到机器行为主义
社会依赖演化网调控的Agent服务协同自适应
  • 批准号:
    61375071
  • 项目类别:
    面上项目
  • 资助金额:
    78.0万元
  • 批准年份:
    2013
  • 负责人:
    高济
  • 依托单位:
生物素-亲和素介导超声造影剂对乳腺癌血管生成分子靶向显像的研究
  • 批准号:
    30670580
  • 项目类别:
    面上项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2006
  • 负责人:
    李颖嘉
  • 依托单位: